Search Results - "LEDERMANN, J"

PARP inhibitors in ovarian cancer by Ledermann, J A

“…Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy…”
Get full text

Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines by Colombo, N., Ledermann, J.A.

Get full text

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies by Lee, J-m., Ledermann, J.A., Kohn, E.C.

“…Poly(ADP-ribose)polymerase inhibitors (PARPis) have shown promising activity in patients with BRCA1/2 mutation-associated (BRCA1/2MUT+) ovarian and breast…”
Get full text

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer by Mirza, M.R., Pignata, S., Ledermann, J.A.

“…For several decades, the systemic treatment of ovarian cancer has involved chemotherapy, with the relatively recent addition of antiangiogenic strategies given…”
Get full text

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments by Ledermann, J.A., Canevari, S., Thigpen, T.

“…In cancer therapy, molecularly targeted agents have the potential to maximize antitumor efficacy while minimizing treatment-related toxicity. However, these…”
Get full text

Front-line therapy of advanced ovarian cancer: new approaches by Ledermann, J A

“…The 5-year survival of ovarian cancer has slowly increased but to date much of this has been due to the use of more lines of treatment rather than better…”
Get full text

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Oaknin, A., Bosse, T.J., Creutzberg, C.L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M.R., Ledermann, J.A., Colombo, N.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing endometrial cancer.•The guideline covers clinical and pathological diagnosis,…”
Get full text

Safety and dose modification for patients receiving niraparib by Berek, J.S., Matulonis, U.A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., Ledermann, J., Pineda, M., Ellard, S., Sehouli, J., Gonzalez-Martin, A., Berton-Rigaud, D., Madry, R., Reinthaller, A., Hazard, S., Guo, W., Mirza, M.R.

“…Niraparib is a poly(ADP-ribose) polymerase inhibitor approved in the USA and Europe for maintenance treatment of adult patients with recurrent epithelial…”
Get full text

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Ledermann, J A, Raja, F A, Fotopoulou, C, Gonzalez-Martin, A, Colombo, N, Sessa, C

Get full text

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study by Matulonis, U.A., Shapira-Frommer, R., Santin, A.D., Lisyanskaya, A.S., Pignata, S., Vergote, I., Raspagliesi, F., Sonke, G.S., Birrer, M., Provencher, D.M., Sehouli, J., Colombo, N., González-Martín, A., Oaknin, A., Ottevanger, P.B., Rudaitis, V., Katchar, K., Wu, H., Keefe, S., Ruman, J., Ledermann, J.A.

“…Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous…”
Get full text

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer by Miller, R.E., Leary, A., Scott, C.L., Serra, V., Lord, C.J., Bowtell, D., Chang, D.K., Garsed, D.W., Jonkers, J., Ledermann, J.A., Nik-Zainal, S., Ray-Coquard, I., Shah, S.P., Matias-Guiu, X., Swisher, E.M., Yates, L.R.

“…Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is…”
Get full text

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease by Colombo, N, Sessa, C, du Bois, A, Ledermann, J, McCluggage, W G, McNeish, I, Morice, P, Pignata, S, Ray-Coquard, I, Vergote, I, Baert, T, Belaroussi, I, Dashora, A, Olbrecht, S, Planchamp, F, Querleu, D

“…Abstract The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society…”
Get full text

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R.E., Pothuri, B., Ray-Coquard, I., Tan, D.S.P., Bellet, E., Oaknin, A., Ledermann, J.A.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing epithelial ovarian cancer.•The guideline covers clinical and pathological…”
Get full text

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004) by Ruers, T., Punt, C., Van Coevorden, F., Pierie, J.P.E.N., Borel-Rinkes, I., Ledermann, J.A., Poston, G., Bechstein, W., Lentz, M.A., Mauer, M., Van Cutsem, E., Lutz, M.P., Nordlinger, B.

“…This study investigates the possible benefits of radiofrequency ablation (RFA) in patients with non-resectable colorectal liver metastases. This phase II…”
Get full text

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline by Sessa, C., Balmaña, J., Bober, S.L., Cardoso, M.J., Colombo, N., Curigliano, G., Domchek, S.M., Evans, D.G., Fischerova, D., Harbeck, N., Kuhl, C., Lemley, B., Levy-Lahad, E., Lambertini, M., Ledermann, J.A., Loibl, S., Phillips, K.-A., Paluch-Shimon, S.

“…•It provides recommendations for risk reduction and screening in hereditary breast and ovarian cancer syndrome.•It focuses on risk reduction and screening…”
Get full text

Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control by Glynne-Jones, R., Counsell, N., Quirke, P., Mortensen, N., Maraveyas, A., Meadows, H.M., Ledermann, J., Sebag-Montefiore, D.

“…In stage III colon cancer, oxaliplatin/5-fluorouracil (5-FU)-based adjuvant chemotherapy (FOLFOX) improves disease-free survival (DFS) and overall survival…”
Get full text

The systemic treatment of recurrent ovarian cancer revisited by Baert, T., Ferrero, A., Sehouli, J., O'Donnell, D.M., González-Martín, A., Joly, F., van der Velden, J., Blecharz, P., Tan, D.S.P., Querleu, D., Colombo, N., du Bois, A., Ledermann, J.A.

“…Treatment approaches for relapsed ovarian cancer have evolved over the past decade from a calendar-based decision tree to a patient-oriented biologically…”
Get full text

A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer by McCormack, M, Kadalayil, L, Hackshaw, A, Hall-Craggs, M A, Symonds, R P, Warwick, V, Simonds, H, Fernando, I, Hammond, M, James, L, Feeney, A, Ledermann, J A

“…Background: We investigated the feasibility of dose-dense neoadjuvant chemotherapy (NACT) with paclitaxel and carboplatin before radical chemoradiation (CRT)…”
Get full text

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I) by Northover, J, Glynne-Jones, R, Sebag-Montefiore, D, James, R, Meadows, H, Wan, S, Jitlal, M, Ledermann, J

“…Background: The first UKCCCR Anal Cancer Trial (1996) demonstrated the benefit of chemoradiation over radiotherapy (RT) alone for treating epidermoid anal…”
Get full text

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial by Frenel, J.S., Kim, J.W., Aryal, N., Asher, R., Berton, D., Vidal, L., Pautier, P., Ledermann, J.A., Penson, R.T., Oza, A.M., Korach, J., Huzarski, T., Pignata, S., Colombo, N., Park-Simon, T.W., Tamura, K., Sonke, G.S., Freimund, A.E., Lee, C.K., Pujade-Lauraine, E.

“…In the SOLO2 trial (ENGOT Ov-21; NCT01874353), maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and BRCA mutation…”
Get full text